| Objective To investigate the regulatory effect of serine protease inhibitor a3n (Serpina3n) on osteogenic differentiation in the bone tissue of estrogen-deficient rats and its impact on the bone morphogenetic protein-2 (BMP-2)/SMAD family member 1 (Smad1)/Runt-related transcription factor 2 (Runx2) signaling pathway. Methods Bilateral ovariectomy (OVX) was performed to establish an estrogen-deficient rat model. Rats were divided into the following groups: sham group, OVX group, OVX+pcDNA-Serpina3n group (intravenous injection of Serpina3n-overexpressing recombinant plasmid), OVX+pcDNA-null group (intravenous injection of empty plasmid), OVX+pcDNA-Serpina3n+ArnicolideC group (combined with BMP-2 activator), OVX+pcDNA-Serpina3n+rhSmad1 group (combined with recombinant human Smad1 protein), and OVX+pcDNA-Serpina3n+rhRunx2 group (combined with recombinant human Runx2 protein). Alkaline phosphatase (ALP) and tartrate-resistant acid phosphatase (TRACP) levels in the bone tissue were measured using assay kits. Hematoxylin-eosin (HE) staining was used to observe pathological indicators such as trabecular bone number, thickness, and cortical bone thickness. Western blotting was performed to detect protein expressions of Serpina3n, BMP-2, Smad1, and Runx2. Alizarin red staining was used to assess bone tissue mineralization. Results Compared to the sham group, the OVX group showed significantly reduced ALP and TRACP levels, trabecular bone number, trabecular thickness, cortical thickness, and mineralization (all P<0.05), while Serpina3n protein expression increased significantly (P<0.05). Overexpression of Serpina3n (OVX+pcDNA-Serpina3n group) further suppressed these indicators (ALP, TRACP, trabecular bone number, cortical thickness, mineralization) and down-regulated BMP-2, Smad1, and Runx2 protein expressions compared to the OVX+pcDNA-null group (all P<0.05). Interventions with Arnicolide C, rhSmad1, and rhRunx2 (OVX+pcDNA-Serpina3n+ArnicolideC/rhSmad1/rhRunx2 groups) significantly reversed these effects and up-regulated BMP-2/Smad1/Runx2 pathway protein expressions compared to the OVX+pcDNA-Serpina3n group (all P<0.05). Conclusion Overexpression of Serpina3n exacerbates osteogenic differentiation impairment in estrogen-deficient rats by inhibiting the BMP-2/Smad1/Runx2 signaling pathway. Activation of this pathway partially reverses the inhibitory effects of Serpina3n, suggesting its potential as a therapeutic target for osteoporosis. |